The final order moves two specific categories of marijuana from Schedule I to Schedule III. First, it reclassifies drug products containing marijuana that have been approved by the U.S. Food and Drug ...
The treatment, developed by Regeneron Pharmaceuticals, is for a very rare form of deafness. But it represents a medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results